Mucosal healing has emerged as an important therapeutic endpoint in the management of inflammatory bowel disease IBD, but few clinical trials have incorporated it as an outcome, and limited data exist to guide the selection of therapy based on comparative effectiveness in achieving this endpoint.
A recent review of FDA-approved drugs that treat IBD concludes that biologic treatments not only relieve IBD symptoms, they also maintain intestinal health. The study, published on March 22, 2017, in Alimentary Pharmacology & Therapeutics, aimed to examine the efficacy of each therapeutic class of FDA-approved IBD drugs in inducing and maintaining mucosal healing in moderate to severe Crohn’s disease (CD) and ulcerative colitis (UC) by performing a meta-analysis of existing data on these therapeutic endpoints.
Researchers led by Aurada Cholapranee, MD, of the Department of Internal Medicine at Montefiore Medical Center, New York, analyzed the following medications: azathioprine (Imuran), methotrexate (Trexall), mercaptopurine (Purinethol), infliximab (Remicade), adalimumab (Humira), certolizumab (Cimzia), golimumab (Simponi), natalizumab (Tysabri), and vedolizumab (ENTYVIO). These medications comprise drug classes of immunosuppressive agents, anti-tumor necrosis factor alpha (anti-TNF), and anti-integrin monoclonal antibody therapy.
The meta-analysis was conducted using 12 randomized, controlled trials that included studies of both induction and maintenance for UC and CD. The follow-up durations were 6 to 12 weeks for induction and 32 to 54 weeks for maintenance trials.
The researchers concluded that, in general, the biologic treatments Remicade and Humira, both of which target TNF-alpha, were much more effective at maintaining mucosal healing in CD compared with placebo controls (28% versus 1%, respectively). With respect to UC, medicines targeting both TNFs and integrins (proteins involved in cellular adhesion and stability) were more effective than placebo controls in inducing (45% versus 30%) and maintaining (33% versus 18%) mucosal healing.
The investigators found that in UC, Humira was inferior to Remicade for the induction of mucosal healing; both medications were similar for CD. “We demonstrated that both anti-TNF and anti-integrin biological agents are effective for inducing and maintaining mucosal healing in UC, and anti-TNF therapies in CD,” the authors concluded. But between-drug differences in efficacy do exist within each therapeutic class, they noted, particularly for induction of mucosal healing in UC, with Remicade or combination therapy being the preferred strategy.
The researchers noted that there is an important and urgent need for data demonstrating efficacy of all approved agents in achieving mucosal healing to truly inform comparative effectiveness and patient care to achieve better outcomes.
Spanish Real-World Study: Adalimumab Biosimilar MSB11022 Safe, Effective in IBD
May 18th 2024A real-world study in Spain on inflammatory bowel disease (IBD) patients found no meaningful changes in clinical or biochemical markers or differences in effectiveness between the adalimumab originator and the biosimilar MSB11022 (Idacio; Fresenius Kabi) in adalimumab-naïve patients.
What AmerisourceBergen's Report Reveals About Payers, Biosimilar Pricing Trends
May 28th 2023On this episode of Not So Different, Tasmina Hydery and Brian Biehn from AmerisourceBergen discussed results from a recent survey, that were also presented at Asembia 2023, diving into the payer perspective on biosimilars and current pricing trends across the US biosimilar industry.
AMCP Posters Tackle Interchangeability and Medicaid, Factors Driving Biosimilar Access
April 24th 2024Two posters from the Academy of Managed Care Pharmacy (AMCP) annual meeting explore how an interchangeable insulin glargine biosimilar plays into Medicaid budgets and the top factors driving access to biosimilars.
Pipelines and Preparation: How the US Can Prepare for More RA Biosimilars
April 16th 2023What can practices do to prepare for all the biosimilars to treat rheumatoid arthritis (RA) coming down the pipeline? And how can they ensure that the lower-than-anticipated adoption rates for infliximab biosimilars are not repeated? Robert Zutaut, RPh, from McKesson Provider Solutions, tackles all this and more on this episode of Not So Different.
Global Biosimilar Market Projected to Reach $1.3 Trillion by 2032
April 11th 2024The global biosimilar market is projected to surge from $25.1 billion in 2022 to approximately $1.3 trillion by 2032, with a compound annual growth rate of 17.6%, driven mainly by the increasing prevalence of cancer and the cost-effectiveness of biosimilars, as outlined in a report by Towards Healthcare.
Study: More Biosimilar Competition Is Not Lowering Patient OOP Costs
March 29th 2024Despite more biosimilars entering the market and generating significant savings for payers and health care systems, these savings are not resulting in lower out-of-pocket (OOP) costs for patients, according to a recent study.